Page last updated: 2024-10-16

adenine and Drug Overdose

adenine has been researched along with Drug Overdose in 2 studies

Drug Overdose: Accidental or deliberate use of a medication or street drug in excess of normal dosage.

Research Excerpts

ExcerptRelevanceReference
"A reversible acute renal failure with no proximal tubulopathy and neuropsychiatric issues are discussed."1.51Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide. ( Álvarez, H; Díaz-Cambre, H; García-González, J; Llibre, JM; Mariño, A; Valcarce, N, 2019)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Álvarez, H1
Mariño, A1
Valcarce, N1
García-González, J1
Díaz-Cambre, H1
Llibre, JM1
Vanichseni, S1
Martin, M1
Suntharasamai, P1
Sangkum, U1
Mock, PA1
Gvetadze, RJ1
Curlin, ME1
Leethochawalit, M1
Chiamwongpaet, S1
Chaipung, B1
McNicholl, JM1
Paxton, LA1
Kittimunkong, S1
Choopanya, K1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Study of the Safety and Efficacy of Daily Tenofovir to Prevent HIV Infection Among Injection Drug Users in Bangkok, Thailand[NCT00119106]Phase 2/Phase 32,413 participants (Actual)Interventional2005-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Adherence to Study Drug/Placebo

Mean number of days that participants took study drug based on study drug diaries by study group. (NCT00119106)
Timeframe: Participants were asked about adherence at 3 month visits, up to 6.9 years.

Interventiondays (Mean)
Tenofovir84
Placebo84

Adverse Events

Number of Participants with adverse clinical events in tenofovir and placebo arms (NCT00119106)
Timeframe: Up to 6.9 years

Interventionparticipants (Number)
Tenofovir1098
Placebo1083

HIV Viral Load Copies/mL Measured at First Positive HIV Test Result by Group

Plasma HIV RNA concentrations. (NCT00119106)
Timeframe: Among people who seroconverted, viral load was measured at month 1, 2, and every 4 months after HIV seroconversion

InterventionCopies/mL (Mean)
Tenofovir929829
Placebo120061

Number of Participants Reporting Injecting and Sharing Needles

"Number of Participants reporting injecting and sharing needles:~Assessed injecting and sharing at baseline and every 3 months during follow-up. We used GEE to determine if there was a significant decline in injecting and sharing." (NCT00119106)
Timeframe: Participants were asked about injecting and needle sharing behaviors at enrollment and every 3 month visit, up to 6.9 years

Interventionparticipants (Number)
Tenofovir58
Placebo59

Number of Participants With Tenofovir-associated Resistance Mutations.

Measure tenofovir associated resistance mutations (ie, K65R and K70E) in amplified viral RNA specimens from HIV-positive participants in the placebo and tenofovir groups. (NCT00119106)
Timeframe: Specimens collected at the time of HIV seroconversion

InterventionParticipants (Count of Participants)
Tenofovir0
Placebo0

Number Participants Who Reported More Than One Sexual Partner at Baseline

Number of participants (NCT00119106)
Timeframe: At enrolment

InterventionParticipants (Count of Participants)
Tenofovir Group251
Placebo Group271

Rates of HIV Seroconversion

Kaplan Meier survival curve. (NCT00119106)
Timeframe: From date of randomization until the date of first documented seroconversion or date of death from any cause, whichever came first, assessed for an average of 4.0 years, with a maximum duration of 6.9 years

InterventionInfections/ 100 person-years (Number)
Tenofovir17
Placebo33

Renal Toxicity

Number of Participants with Grade 3 or 4 Renal Laboratory Toxicities (NCT00119106)
Timeframe: Blood tested for creatinine level at enrollment and every 3 months, up to 6.9 years

Interventionparticipants (Number)
Tenofovir3
Placebo3

Trials

1 trial available for adenine and Drug Overdose

ArticleYear
High Mortality Among Non-HIV-Infected People Who Inject Drugs in Bangkok, Thailand, 2005-2012.
    American journal of public health, 2015, Volume: 105, Issue:6

    Topics: Accidents, Traffic; Adenine; Adult; Anti-HIV Agents; Cause of Death; Double-Blind Method; Drug Overd

2015

Other Studies

1 other study available for adenine and Drug Overdose

ArticleYear
Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.
    Infection, 2019, Volume: 47, Issue:1

    Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Overdose; Emtricitabine; HIV

2019